Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease

Introduction: Corona Virus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. The aim of this study was to investigate the impact of being on an Angiotensin-Converting Enzyme Inhibitors (ACEI) and/or Angiotensin Receptor B...

Full description

Bibliographic Details
Main Authors: Rawan ElAbd, Dana AlTarrah, Sarah AlYouha, Hamad Bastaki, Sulaiman Almazeedi, Mohannad Al-Haddad, Mohammad Jamal, Salman AlSabah
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Medicine
Subjects:
ACEi (angiotensin conversing enzyme inhibitor)
ARB (angiotensin II AT1 receptor blocker)
ICU–intensive care unit
COVID−19
mortality
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.600385/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.600385/full

Similar Items